Cat. No.: HY-N0039

Ginsenoside Rb1

(Synonyms: Gypenoside III)

16 Cited Publications

Customer Review

Based on 16 publication(s) in Google Scholar

Ginsenoside Rb1, a main constituent of the root of Panax ginseng, inhibits Na⁺, K⁺-ATPase activity with an IC₅₀ of 6.3±1.0 μM. Ginsenoside also inhibits IRAK-1 activation and phosphorylation of NF-κB p65 .

For research use only. We do not sell to patients.

Purity: 99.75%
CAS No.: 41753-43-9
Formula: C₅₄H₉₂O₂₃
Molecular Weight:1109.29

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Ginsenoside Rb1 Chemical Structure

CAS No.: 41753-43-9

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (16)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]^[2]^[3]^[6]

Na⁺, K⁺-ATPase

6.3 μM (IC₅₀)

IRAK-1

p65

Autophagy

Mitophagy

HSV-1

All IRAK Isoforms :

All NF-κB Isoforms :

All HSV Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
Erythrocyte	IC₅₀	3.18 μM Compound: 70	Inhibition of AAPH-induced hemolysis of human erythrocytes Inhibition of AAPH-induced hemolysis of human erythrocytes	[PMID: 32006794]

In Vitro

Rat brain microsomal Na⁺, K⁺-ATPase activity is inhibited significantly and rapidly by Ginsenoside Rb1. The IC₅₀ of Ginsenoside Rb1 for Na⁺,K⁺-ATPase is 6.3±1.0 μM. The inhibition is enhanced with increasing the concentration of Ginsenoside Rb1 or decreasing that of Na⁺ and K⁺. Kinetic analysis reveals that Ginsenoside is an uncompetitive inhibitor with respect to ATP^[1]. Ginsenoside Rb1 significantly inhibits the activation of interleukin-1 receptor-associated kinase-1 (IRAK-1), IKK-β, NF-κB, and MAP kinases (ERK, JNK, and p-38); however, interaction between LPS and Toll-like receptor-4, IRAK-4 activation and IRAK-2 activation are unaffected^[2]. Ginsenoside Rb1 is an ingredient of a Chinese medicine Panax ginseng. Ginsenoside Rb1 is a major bioactive compound in the regulating pregnane X receptor (PXR)/NF-κB signaling. Ginsenoside Rb1 is the compound with potent anti-inflammatory activity in ginseng saponin extract (GSE). The concentration for Ginsenoside Rb1 (10 μM) is optimized from a preliminary study to ensure sufficient anti-inflammatory activity and without apparent cytotoxicity. Ginsenoside Rb1 significantly reduces TNF-α-induced upregulation of IL-1β and iNOS mRNA levels, and restores the mRNA levels of PXR and CYP3A4 in LS174T cells. TNF-α causes a significant reduction in PXR protein levels and increase in the ratio of phosphorylated to total NF-κB p65, both of which are significantly abrogated by Ginsenoside Rb1^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Ginsenoside Rb1 at the both doses of 30 mg/kg and 60 mg/kg significantly attenuates the histological lung injury. Ginsenoside Rb1 at the dose of 30 mg/kg and 60 mg/kg both significantly attenuates the histological intestine injury^[4]. Ginsenoside Rb1 (Rb1), an ingredient of a Chinese medicine Panax ginseng, has beneficial effects on mesentery microvascular hyperpermeability induced by Lipopolysaccharide (LPS) and the underlying mechanisms. In some rats, Ginsenoside Rb1 (5 mg/kg per hour) is administrated through the left jugular vein 30 min after LPS infusion. Ginsenoside Rb1 decreases caveolae number in endothelial cells of microvessels. Ginsenoside Rb1 ameliorates microvascular hyperpermeability after the onset of endotoxemia and improves intestinal edema through inhibiting caveolae formation and junction disruption, which is correlated to suppression of NF-κB and Src activation^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 41753-43-9
Appearance Solid
Molecular Weight 1109.29
Formula C₅₄H₉₂O₂₃
Color White to off-white
SMILES

C[C@@]([C@@]12C)(CC[C@@]3([H])C4(C)C)[C@@](C[C@@H](O)[C@]1([H])[C@]([C@@](CC/C=C(C)/C)(C)O[C@@H]([C@@H]([C@@H](O)[C@@H]5O)O)O[C@@H]5CO[C@@H]([C@@H]([C@@H](O)[C@@H]6O)O)O[C@@H]6CO)([H])CC2)([H])[C@]3(CC[C@@H]4O[C@@](O[C@H](CO)[C@@H](O)[C@@H]7O)([H])[C@@H]7O[C@]([C@@H]([C@@H](O)[C@@H]8O)O)([H])O[C@@H]8CO)C
Synonyms

Gypenoside III
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (16)

All Cell Proliferation/Viability AssayBio/Physico-chemical AssayCell Imaging/StainingIn Vivo Efficacy StudyApoptosis AnalysisHistological Imaging/StainingIHC

Sort by:

Journal Impact Factor

J Nanobiotechnology

Overcoming acquired immunotherapy resistance in non-small cell lung cancer using ginsenoside Rb1-loaded, peptide-enhanced exosome delivery systems. [Abstract]

2025 Jun 13;23(1):443. PMID: 40514658

Ginsenoside Rb1 purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2025 Jun 13;23(1):443. [Abstract]

Ginsenoside Rb1 (5 mg/kg; via tail vein injection on days 7, 14, and 21 post-tumor implantation) in BALB/c nude mice (PI3K-mutated A549 cells) exhibited significantly decreased tumor weight and reduced tumor growth rate compared to the Control group. A Schematic timeline of the animal experiment; B Images and weights of dissected tumors from subcutaneous xenograft model mice in each group. C Tumor growth curves for mice in each group;

Ginsenoside Rb1 purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2025 Jun 13;23(1):443. [Abstract]

Ginsenoside Rb1 (5 mg/kg; via tail vein injection on days 7, 14, and 21 post-tumor implantation) in BALB/c nude mice (PI3K-mutated A549 cells) reduced infiltration of inflammatory cells, tighter cell arrangement, more normal cell morphology, uniform cell nuclei, and clear nucleoli. H&E staining images of tumors from each group.

Ginsenoside Rb1 purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2025 Jun 13;23(1):443. [Abstract]

Ginsenoside Rb1 (5 mg/kg; via tail vein injection on days 7, 14, and 21 post-tumor implantation) in BALB/c nude mice (PI3K-mutated A549 cells) compared to the Control group, with a more substantial decrease in Ki67 expression in the Rb1@T-exo group.
Cell Death Dis

A dual Keap1 and p47phox inhibitor Ginsenoside Rb1 ameliorates high glucose/ox-LDL-induced endothelial cell injury and atherosclerosis. [Abstract]

2022 Sep 26;13(9):824. PMID: 36163178

Ginsenoside Rb1 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2022 Sep 26;13(9):824. [Abstract]

EA.hy926 ECs were pretreated with Ginsenoside Rb1 (Rb1; 3, 10, and 30 μM) for 30 min before ox-LDL/HG for 24 h, Ginsenoside Rb1 dose-dependently restored the declined cell viability in ox-LDL/HG-challenged ECs.

Ginsenoside Rb1 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2022 Sep 26;13(9):824. [Abstract]

EA.hy926 ECs were pretreated with Ginsenoside Rb1 (Rb1; 3, 10, and 30 μM) for 30 min before ox-LDL/HG for 24 h. Exposure to ox-LDL/HG promoted the generation of MDA, a marker of oxidative stress, while this was concentrationdependently reversed by Rb1 pretreatment.

Ginsenoside Rb1 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2022 Sep 26;13(9):824. [Abstract]

EA.hy926 ECs were pretreated with Ginsenoside Rb1 (Rb1; 3, 10, and 30 μM) for 30 min before ox-LDL/HG for 24 h. Representative images of DHE staining.

Ginsenoside Rb1 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2022 Sep 26;13(9):824. [Abstract]

EA.hy926 ECs were pretreated with Ginsenoside Rb1 (Rb1; 10 μM) for 30 min before ox-LDL/HG for 24 h. A Cell apoptosis measured by flow cytometer. B Apoptosis ratio.

Ginsenoside Rb1 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2022 Sep 26;13(9):824. [Abstract]

EA.hy926 ECs were pretreated with Ginsenoside Rb1 (Rb1; 10 μM) for 30 min before ox-LDL/HG for 24 h. Cell apoptosis measured by TUNEL assay.
Phytomedicine

Rare ginsenoside Rk1 protects against cisplatin-induced auditory damage by regulating the MST1/LONP1 pathway. [Abstract]

2026 Apr 26. PMID: 42097003
Phytomedicine

Ginsenoside Rb1 protects hippocampal neurons in depressed rats based on mitophagy-regulated astrocytic pyroptosis. [Abstract]

2023 Dec:121:155083. PMID: 37722244
Mol Med

Ginsenoside Rb1 affects mitochondrial Ca2+ transport and inhibits fat deposition and fibrosis by regulating the wnt signaling pathway to treat rotator cuff tears via docking with SFRP1. [Abstract]

2024 Dec 2;30(1):240. PMID: 39617900
Mater Des

2024 Sep.
Br J Pharmacol

The plant extract PNS mitigates atherosclerosis via promoting Nrf2-mediated inhibition of ferroptosis through reducing USP2-mediated Keap1 deubiquitination. [Abstract]

2024 Dec;181(23):4822-4844. PMID: 39228119
Chin Med

Ginsenoside Rb1 targets the NRF2-PPARγ-ACSL4 axis to inhibit PTECs ferroptosis. [Abstract]

2026 Jan 8;21(1):19. PMID: 41508002
Drug Des Devel Ther

Cellular and Molecular Mechanisms of Hyperglycemia-Induced Atherosclerosis and Intervention Strategies of Chinese Herbal Medicine. [Abstract]

2026 Apr 23:20:602453. PMID: 42057976
Int J Mol Sci

The RNA Demethyltransferase FTO Regulates Ferroptosis in Major Depressive Disorder. [Abstract]

2025 Jan 26;26(3):1075. PMID: 39940841
Front Pharmacol

Frutescone O from Baeckea frutescens Blocked TLR4-Mediated Myd88/NF-κB and MAPK Signaling Pathways in LPS Induced RAW264.7 Macrophages. [Abstract]

2021 Apr 27:12:643188. PMID: 33986676
Sci Rep

Multi-omics analysis reveals that ginsenoside Rb1 improves prognostic outcomes in sepsis by modulating mitochondrial metabolism MTHFD2 targets. [Abstract]

2026 Feb 1;16(1):6880. PMID: 41622321
Biol Proced Online

Establishment of a mouse lung cancer organoid model and its applications for therapeutic screening. [Abstract]

2025 Jun 16;27(1):21. PMID: 40524168
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607
Research Square Print

September 1st, 2022.
Research Square Preprint

2021 Feb.

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (90.15 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : ≥ 33.33 mg/mL (30.05 mM)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

0.9015 mL

4.5074 mL

9.0148 mL

5 mM

0.1803 mL

0.9015 mL

1.8030 mL

10 mM

0.0901 mL

0.4507 mL

0.9015 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (2.25 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (2.25 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (2.25 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Protocol

Cell Assay^[3]

LS174T cells are seeded in cell imaging dish. After overnight incubation, cells are treated with GSE (100 μg/mL), Ginsenoside Rb1 (10 μM), or CK (10 μM) for 3 hours, followed by an additional incubation with or without TNF-α (20 ng/ml) for 6 hours. At the end of the incubation, cells are harvested and fixed with 4% paraformaldehyde solution at 20°C for 20 minutes. After washing in PBS, cells are permeabilized with 0.2% Triton X-100 in PBS at room temperature for 5 minutes. After incubation in blocking buffer containing 0.1% Triton X-100 and 5% bovine serum albumin, cells are incubated with rabbit NF-κB p65 antibody at 4°C overnight and then with Alexa Fluor 488-conjugated anti-rabbit IgG antibody at room temperature for 30 minutes in 1% bovine serum albumin in PBS. Fluorescence photographs are obtained using a Zeiss 710 confocal microscope^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[4]^[5]

Mice^[4]
Male C57BL/6 mice (9-12 weeks old; 17-22 g) are randomly allocated into eight groups (n=8 in each group): (1) Sham surgical preparation including isolation of the superior mesenteric artery (SMA) without occlusion is performed (Sham); (2) mice are subjected to II/R without treatment (II/R); (3) mice are subjected to II/R with treatment of normal saline 10 minutes before reperfusion (II/R+NS); (4), (5) mice are treated with 30 mg/kg (II/R+Rb1-30) or 60 mg/kg (II/R+Rb1-60) Ginsenoside Rb1, in which surgery is performed as in the II/R group with administration of the Ginsenoside Rb1 intraperitoneally 10 minutes before reperfusion; (6) mice are subjected to Sham surgery and treated with ATRA (ATRA+Sham), which is the inhibitor of Nrf2/ARE signaling pathway; (7) mice are subjected to II/R and treated with ATRA (ATRA+II/R); (8) mice are subjected to II/R and treated with ATRA and 60 mg/kg Ginsenoside Rb1 as group 5 (ATRA+II/R+Rb1-60). During the last two weeks before the operation, the mice in the group 6, 7, 8 receive ATRA i.p. daily at 10 mg/kg and fed on a vitamin A-deficient diet, and the mice in the other groups receive the equivalent volume of corn oil and fed on a control normal diet.
Rats^[5]
Male Wistar rats weighing 200-250 g are used. The rats are randomly divided into four groups, 26 animals in each. After being anesthetized with urethane (2 g/kg body wt im), the left femoral vein and left jugular vein of the rat are cannulated. In the LPS group, LPS solution in saline is infused (5 mg/kg per hour) for 90 min via the left femoral vein. The vehicle, instead of LPS solution, is administrated in Sham and Ginsenoside Rb1 alone (Rb1, 5 mg/kg) groups. In the Rb1 posttreatment (LPS+Rb1) group, Ginsenoside Rb1 solution is infused continuously through the left jugular vein 30 min after LPS administration at the dose of 5 mg/kg. Ginsenoside Rb1 solution and the same volume of saline are infused in Ginsenoside Rb1 and Sham groups, respectively, without subsequent LPS administration. In a separate set of experiments, the rats are anesthetized with 2% penobarbital sodium (60 mg/kg body wt ip), and saline, LPS, and Ginsenoside Rb1. After recovery from anesthesia, the animals are allowed access to water and rodent chow, and survival rate is recorded over time until 4 days after LPS stimulation.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (289 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Cao J, et al. Inhibitory effects of ginsenoside Rg1 and Rb1 on rat brain microsomal Na⁺,K⁺-ATPase activity. Zhongguo Yao Li Xue Bao. 1990 Jan;11(1):10-4. [Content Brief]

[2]. Zhang J, et al. Ginsenosides Regulate PXR/NF-κB Signaling and Attenuate Dextran Sulfate Sodium-Induced Colitis. Drug Metab Dispos. 2015 Aug;43(8):1181-9. [Content Brief]

[3]. Joh EH, et al. Ginsenoside Rb1 and its metabolite compound K inhibit IRAK-1 activation--the key step of inflammation. Biochem Pharmacol. 2011 Aug 1;82(3):278-86. [Content Brief]

[4]. Jiang Y, et al. Ginsenoside Rb1 Treatment Attenuates Pulmonary Inflammatory Cytokine Release and Tissue Injury following Intestinal Ischemia Reperfusion Injury in Mice. Oxid Med Cell Longev. 2015;2015:843721. [Content Brief]

[5]. Zhang Y, et al. Ginsenoside Rb1 ameliorates lipopolysaccharide-induced albumin leakage from rat mesenteric venules by intervening in both trans- and paracellular pathway. Am J Physiol Gastrointest Liver Physiol. 2014 Feb 15;306(4):G289-300. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	0.9015 mL	4.5074 mL	9.0148 mL	22.5369 mL
	5 mM	0.1803 mL	0.9015 mL	1.8030 mL	4.5074 mL
	10 mM	0.0901 mL	0.4507 mL	0.9015 mL	2.2537 mL
	15 mM	0.0601 mL	0.3005 mL	0.6010 mL	1.5025 mL
	20 mM	0.0451 mL	0.2254 mL	0.4507 mL	1.1268 mL
	25 mM	0.0361 mL	0.1803 mL	0.3606 mL	0.9015 mL
	30 mM	0.0300 mL	0.1502 mL	0.3005 mL	0.7512 mL
DMSO	40 mM	0.0225 mL	0.1127 mL	0.2254 mL	0.5634 mL
	50 mM	0.0180 mL	0.0901 mL	0.1803 mL	0.4507 mL
	60 mM	0.0150 mL	0.0751 mL	0.1502 mL	0.3756 mL
	80 mM	0.0113 mL	0.0563 mL	0.1127 mL	0.2817 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Ginsenoside Rb1

16 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Ginsenoside Rb1

Antioxidant Compound Library

Differentiation Inducing Compound Library

Glycoside Compound Library

Lipid Compound Library

Oxygen Sensing Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Pyroptosis Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Mitochondria-Targeted Compound Library

Transcription Factor-Targeted Library

Food-Sourced Compound Library

Anti-Liver Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Antiviral Traditional Chinese Medicine Active Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Membrane Protein-targeted Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Mitophagy Compound Library

Bioactive Compound Library Max

Kinase Inhibitor Library Mini

Natural Product Library Plus

Bioactive Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Posttranslational Modification Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Natural Product and Natural Product-Like Compound Library

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

Membrane Transporter/Ion Channel Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Antiviral Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Publications Citing Use of MedChemExpress (MCE) Ginsenoside Rb1

All IRAK Isoforms

All NF-κB Isoforms

All HSV Isoforms

Biological Activity

Chemical Information

Publications (16)

Solvent & Solubility

Protocol